Allergan PLC acquires autoimmune-focused Vitae for $639mm
Executive Summary
Allergan PLC acquired public biotech Vitae Pharmaceuticals Inc. (computational drug design), paying $21 per share (a 175% premium) in cash for all Vitae outstanding shares, valuing the transaction at $639mm.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice